Rethinking drug safety signal detection and causality assessment in the age of AI: the risks of incomplete data and biased insights Article Swipe
Priyanka Chhikara
,
Tarek A. Hammad
·
YOU?
·
· 2025
· Open Access
·
· DOI: https://doi.org/10.3389/fdsfr.2025.1678074
YOU?
·
· 2025
· Open Access
·
· DOI: https://doi.org/10.3389/fdsfr.2025.1678074
Related Topics
Concepts
No concepts available.
Metadata
- Type
- article
- Language
- en
- Landing Page
- https://doi.org/10.3389/fdsfr.2025.1678074
- https://www.frontiersin.org/journals/drug-safety-and-regulation/articles/10.3389/fdsfr.2025.1678074/pdf
- OA Status
- diamond
- Cited By
- 1
- References
- 17
- OpenAlex ID
- https://openalex.org/W4414248346
All OpenAlex metadata
Raw OpenAlex JSON
- OpenAlex ID
-
https://openalex.org/W4414248346Canonical identifier for this work in OpenAlex
- DOI
-
https://doi.org/10.3389/fdsfr.2025.1678074Digital Object Identifier
- Title
-
Rethinking drug safety signal detection and causality assessment in the age of AI: the risks of incomplete data and biased insightsWork title
- Type
-
articleOpenAlex work type
- Language
-
enPrimary language
- Publication year
-
2025Year of publication
- Publication date
-
2025-09-16Full publication date if available
- Authors
-
Priyanka Chhikara, Tarek A. HammadList of authors in order
- Landing page
-
https://doi.org/10.3389/fdsfr.2025.1678074Publisher landing page
- PDF URL
-
https://www.frontiersin.org/journals/drug-safety-and-regulation/articles/10.3389/fdsfr.2025.1678074/pdfDirect link to full text PDF
- Open access
-
YesWhether a free full text is available
- OA status
-
diamondOpen access status per OpenAlex
- OA URL
-
https://www.frontiersin.org/journals/drug-safety-and-regulation/articles/10.3389/fdsfr.2025.1678074/pdfDirect OA link when available
- Cited by
-
1Total citation count in OpenAlex
- Citations by year (recent)
-
2025: 1Per-year citation counts (last 5 years)
- References (count)
-
17Number of works referenced by this work
Full payload
| id | https://openalex.org/W4414248346 |
|---|---|
| doi | https://doi.org/10.3389/fdsfr.2025.1678074 |
| ids.doi | https://doi.org/10.3389/fdsfr.2025.1678074 |
| ids.pmid | https://pubmed.ncbi.nlm.nih.gov/40978506 |
| ids.openalex | https://openalex.org/W4414248346 |
| fwci | 3.43037969 |
| type | article |
| title | Rethinking drug safety signal detection and causality assessment in the age of AI: the risks of incomplete data and biased insights |
| biblio.issue | |
| biblio.volume | 5 |
| biblio.last_page | 1678074 |
| biblio.first_page | 1678074 |
| topics[0].id | https://openalex.org/T11943 |
| topics[0].field.id | https://openalex.org/fields/30 |
| topics[0].field.display_name | Pharmacology, Toxicology and Pharmaceutics |
| topics[0].score | 0.9944999814033508 |
| topics[0].domain.id | https://openalex.org/domains/1 |
| topics[0].domain.display_name | Life Sciences |
| topics[0].subfield.id | https://openalex.org/subfields/3005 |
| topics[0].subfield.display_name | Toxicology |
| topics[0].display_name | Pharmacovigilance and Adverse Drug Reactions |
| topics[1].id | https://openalex.org/T11636 |
| topics[1].field.id | https://openalex.org/fields/27 |
| topics[1].field.display_name | Medicine |
| topics[1].score | 0.9857000112533569 |
| topics[1].domain.id | https://openalex.org/domains/4 |
| topics[1].domain.display_name | Health Sciences |
| topics[1].subfield.id | https://openalex.org/subfields/2718 |
| topics[1].subfield.display_name | Health Informatics |
| topics[1].display_name | Artificial Intelligence in Healthcare and Education |
| topics[2].id | https://openalex.org/T10582 |
| topics[2].field.id | https://openalex.org/fields/27 |
| topics[2].field.display_name | Medicine |
| topics[2].score | 0.958899974822998 |
| topics[2].domain.id | https://openalex.org/domains/4 |
| topics[2].domain.display_name | Health Sciences |
| topics[2].subfield.id | https://openalex.org/subfields/2739 |
| topics[2].subfield.display_name | Public Health, Environmental and Occupational Health |
| topics[2].display_name | Ethics in Clinical Research |
| is_xpac | False |
| apc_list | |
| apc_paid | |
| language | en |
| locations[0].id | doi:10.3389/fdsfr.2025.1678074 |
| locations[0].is_oa | True |
| locations[0].source.id | https://openalex.org/S4210181589 |
| locations[0].source.issn | 2674-0869 |
| locations[0].source.type | journal |
| locations[0].source.is_oa | True |
| locations[0].source.issn_l | 2674-0869 |
| locations[0].source.is_core | True |
| locations[0].source.is_in_doaj | True |
| locations[0].source.display_name | Frontiers in Drug Safety and Regulation |
| locations[0].source.host_organization | https://openalex.org/P4310320527 |
| locations[0].source.host_organization_name | Frontiers Media |
| locations[0].source.host_organization_lineage | https://openalex.org/P4310320527 |
| locations[0].source.host_organization_lineage_names | Frontiers Media |
| locations[0].license | cc-by |
| locations[0].pdf_url | https://www.frontiersin.org/journals/drug-safety-and-regulation/articles/10.3389/fdsfr.2025.1678074/pdf |
| locations[0].version | publishedVersion |
| locations[0].raw_type | journal-article |
| locations[0].license_id | https://openalex.org/licenses/cc-by |
| locations[0].is_accepted | True |
| locations[0].is_published | True |
| locations[0].raw_source_name | Frontiers in Drug Safety and Regulation |
| locations[0].landing_page_url | https://doi.org/10.3389/fdsfr.2025.1678074 |
| locations[1].id | pmid:40978506 |
| locations[1].is_oa | False |
| locations[1].source.id | https://openalex.org/S4306525036 |
| locations[1].source.issn | |
| locations[1].source.type | repository |
| locations[1].source.is_oa | False |
| locations[1].source.issn_l | |
| locations[1].source.is_core | False |
| locations[1].source.is_in_doaj | False |
| locations[1].source.display_name | PubMed |
| locations[1].source.host_organization | https://openalex.org/I1299303238 |
| locations[1].source.host_organization_name | National Institutes of Health |
| locations[1].source.host_organization_lineage | https://openalex.org/I1299303238 |
| locations[1].license | |
| locations[1].pdf_url | |
| locations[1].version | publishedVersion |
| locations[1].raw_type | |
| locations[1].license_id | |
| locations[1].is_accepted | True |
| locations[1].is_published | True |
| locations[1].raw_source_name | Frontiers in drug safety and regulation |
| locations[1].landing_page_url | https://pubmed.ncbi.nlm.nih.gov/40978506 |
| locations[2].id | pmh:oai:doaj.org/article:45b54fbfffec42f5b5efbee20aa97a66 |
| locations[2].is_oa | False |
| locations[2].source.id | https://openalex.org/S4306401280 |
| locations[2].source.issn | |
| locations[2].source.type | repository |
| locations[2].source.is_oa | False |
| locations[2].source.issn_l | |
| locations[2].source.is_core | False |
| locations[2].source.is_in_doaj | False |
| locations[2].source.display_name | DOAJ (DOAJ: Directory of Open Access Journals) |
| locations[2].source.host_organization | |
| locations[2].source.host_organization_name | |
| locations[2].license | |
| locations[2].pdf_url | |
| locations[2].version | submittedVersion |
| locations[2].raw_type | article |
| locations[2].license_id | |
| locations[2].is_accepted | False |
| locations[2].is_published | False |
| locations[2].raw_source_name | Frontiers in Drug Safety and Regulation, Vol 5 (2025) |
| locations[2].landing_page_url | https://doaj.org/article/45b54fbfffec42f5b5efbee20aa97a66 |
| locations[3].id | pmh:oai:europepmc.org:11253115 |
| locations[3].is_oa | True |
| locations[3].source.id | https://openalex.org/S4306400806 |
| locations[3].source.issn | |
| locations[3].source.type | repository |
| locations[3].source.is_oa | False |
| locations[3].source.issn_l | |
| locations[3].source.is_core | False |
| locations[3].source.is_in_doaj | False |
| locations[3].source.display_name | Europe PMC (PubMed Central) |
| locations[3].source.host_organization | https://openalex.org/I1303153112 |
| locations[3].source.host_organization_name | European Bioinformatics Institute |
| locations[3].source.host_organization_lineage | https://openalex.org/I1303153112 |
| locations[3].license | other-oa |
| locations[3].pdf_url | |
| locations[3].version | submittedVersion |
| locations[3].raw_type | Text |
| locations[3].license_id | https://openalex.org/licenses/other-oa |
| locations[3].is_accepted | False |
| locations[3].is_published | False |
| locations[3].raw_source_name | |
| locations[3].landing_page_url | https://www.ncbi.nlm.nih.gov/pmc/articles/12443104 |
| indexed_in | crossref, doaj, pubmed |
| authorships[0].author.id | https://openalex.org/A5113341379 |
| authorships[0].author.orcid | |
| authorships[0].author.display_name | Priyanka Chhikara |
| authorships[0].countries | US |
| authorships[0].affiliations[0].institution_ids | https://openalex.org/I4210112753 |
| authorships[0].affiliations[0].raw_affiliation_string | Global Safety Science, Global Safety and Pharmacovigilance, CSL Behring, King of Prussia, PA, United States |
| authorships[0].institutions[0].id | https://openalex.org/I4210112753 |
| authorships[0].institutions[0].ror | https://ror.org/01jxhxv92 |
| authorships[0].institutions[0].type | company |
| authorships[0].institutions[0].lineage | https://openalex.org/I4210112753, https://openalex.org/I4210153402 |
| authorships[0].institutions[0].country_code | US |
| authorships[0].institutions[0].display_name | CSL (United States) |
| authorships[0].author_position | first |
| authorships[0].raw_author_name | Priyanka Chhikara |
| authorships[0].is_corresponding | True |
| authorships[0].raw_affiliation_strings | Global Safety Science, Global Safety and Pharmacovigilance, CSL Behring, King of Prussia, PA, United States |
| authorships[1].author.id | https://openalex.org/A5046388350 |
| authorships[1].author.orcid | https://orcid.org/0000-0001-8229-4716 |
| authorships[1].author.display_name | Tarek A. Hammad |
| authorships[1].countries | US |
| authorships[1].affiliations[0].institution_ids | https://openalex.org/I4210140176, https://openalex.org/I889937125 |
| authorships[1].affiliations[0].raw_affiliation_string | Medical Safety of Marketed Products Development and Plasma-Derived Therapies, Patient Safety and Pharmacovigilance, Takeda Development Center Americas, Inc., Cambridge, MA, United States |
| authorships[1].institutions[0].id | https://openalex.org/I889937125 |
| authorships[1].institutions[0].ror | https://ror.org/01df6fw27 |
| authorships[1].institutions[0].type | nonprofit |
| authorships[1].institutions[0].lineage | https://openalex.org/I889937125 |
| authorships[1].institutions[0].country_code | US |
| authorships[1].institutions[0].display_name | National Patient Safety Foundation |
| authorships[1].institutions[1].id | https://openalex.org/I4210140176 |
| authorships[1].institutions[1].ror | https://ror.org/03bygaq51 |
| authorships[1].institutions[1].type | company |
| authorships[1].institutions[1].lineage | https://openalex.org/I4210140176, https://openalex.org/I44892455 |
| authorships[1].institutions[1].country_code | US |
| authorships[1].institutions[1].display_name | Takeda (United States) |
| authorships[1].author_position | last |
| authorships[1].raw_author_name | Tarek A. Hammad |
| authorships[1].is_corresponding | False |
| authorships[1].raw_affiliation_strings | Medical Safety of Marketed Products Development and Plasma-Derived Therapies, Patient Safety and Pharmacovigilance, Takeda Development Center Americas, Inc., Cambridge, MA, United States |
| has_content.pdf | True |
| has_content.grobid_xml | True |
| is_paratext | False |
| open_access.is_oa | True |
| open_access.oa_url | https://www.frontiersin.org/journals/drug-safety-and-regulation/articles/10.3389/fdsfr.2025.1678074/pdf |
| open_access.oa_status | diamond |
| open_access.any_repository_has_fulltext | False |
| created_date | 2025-10-10T00:00:00 |
| display_name | Rethinking drug safety signal detection and causality assessment in the age of AI: the risks of incomplete data and biased insights |
| has_fulltext | False |
| is_retracted | False |
| updated_date | 2025-11-06T03:46:38.306776 |
| primary_topic.id | https://openalex.org/T11943 |
| primary_topic.field.id | https://openalex.org/fields/30 |
| primary_topic.field.display_name | Pharmacology, Toxicology and Pharmaceutics |
| primary_topic.score | 0.9944999814033508 |
| primary_topic.domain.id | https://openalex.org/domains/1 |
| primary_topic.domain.display_name | Life Sciences |
| primary_topic.subfield.id | https://openalex.org/subfields/3005 |
| primary_topic.subfield.display_name | Toxicology |
| primary_topic.display_name | Pharmacovigilance and Adverse Drug Reactions |
| cited_by_count | 1 |
| counts_by_year[0].year | 2025 |
| counts_by_year[0].cited_by_count | 1 |
| locations_count | 4 |
| best_oa_location.id | doi:10.3389/fdsfr.2025.1678074 |
| best_oa_location.is_oa | True |
| best_oa_location.source.id | https://openalex.org/S4210181589 |
| best_oa_location.source.issn | 2674-0869 |
| best_oa_location.source.type | journal |
| best_oa_location.source.is_oa | True |
| best_oa_location.source.issn_l | 2674-0869 |
| best_oa_location.source.is_core | True |
| best_oa_location.source.is_in_doaj | True |
| best_oa_location.source.display_name | Frontiers in Drug Safety and Regulation |
| best_oa_location.source.host_organization | https://openalex.org/P4310320527 |
| best_oa_location.source.host_organization_name | Frontiers Media |
| best_oa_location.source.host_organization_lineage | https://openalex.org/P4310320527 |
| best_oa_location.source.host_organization_lineage_names | Frontiers Media |
| best_oa_location.license | cc-by |
| best_oa_location.pdf_url | https://www.frontiersin.org/journals/drug-safety-and-regulation/articles/10.3389/fdsfr.2025.1678074/pdf |
| best_oa_location.version | publishedVersion |
| best_oa_location.raw_type | journal-article |
| best_oa_location.license_id | https://openalex.org/licenses/cc-by |
| best_oa_location.is_accepted | True |
| best_oa_location.is_published | True |
| best_oa_location.raw_source_name | Frontiers in Drug Safety and Regulation |
| best_oa_location.landing_page_url | https://doi.org/10.3389/fdsfr.2025.1678074 |
| primary_location.id | doi:10.3389/fdsfr.2025.1678074 |
| primary_location.is_oa | True |
| primary_location.source.id | https://openalex.org/S4210181589 |
| primary_location.source.issn | 2674-0869 |
| primary_location.source.type | journal |
| primary_location.source.is_oa | True |
| primary_location.source.issn_l | 2674-0869 |
| primary_location.source.is_core | True |
| primary_location.source.is_in_doaj | True |
| primary_location.source.display_name | Frontiers in Drug Safety and Regulation |
| primary_location.source.host_organization | https://openalex.org/P4310320527 |
| primary_location.source.host_organization_name | Frontiers Media |
| primary_location.source.host_organization_lineage | https://openalex.org/P4310320527 |
| primary_location.source.host_organization_lineage_names | Frontiers Media |
| primary_location.license | cc-by |
| primary_location.pdf_url | https://www.frontiersin.org/journals/drug-safety-and-regulation/articles/10.3389/fdsfr.2025.1678074/pdf |
| primary_location.version | publishedVersion |
| primary_location.raw_type | journal-article |
| primary_location.license_id | https://openalex.org/licenses/cc-by |
| primary_location.is_accepted | True |
| primary_location.is_published | True |
| primary_location.raw_source_name | Frontiers in Drug Safety and Regulation |
| primary_location.landing_page_url | https://doi.org/10.3389/fdsfr.2025.1678074 |
| publication_date | 2025-09-16 |
| publication_year | 2025 |
| referenced_works | https://openalex.org/W4221057362, https://openalex.org/W2796212360, https://openalex.org/W4220839569, https://openalex.org/W2116243022, https://openalex.org/W3080627676, https://openalex.org/W4408357602, https://openalex.org/W4386483923, https://openalex.org/W1988714655, https://openalex.org/W4412384358, https://openalex.org/W3004538958, https://openalex.org/W2981869278, https://openalex.org/W4409210035, https://openalex.org/W4391244377, https://openalex.org/W4284971083, https://openalex.org/W4385290206, https://openalex.org/W2969881216, https://openalex.org/W4293340862 |
| referenced_works_count | 17 |
| abstract_inverted_index | |
| cited_by_percentile_year.max | 95 |
| cited_by_percentile_year.min | 91 |
| corresponding_author_ids | https://openalex.org/A5113341379 |
| countries_distinct_count | 1 |
| institutions_distinct_count | 2 |
| corresponding_institution_ids | https://openalex.org/I4210112753 |
| citation_normalized_percentile.value | 0.87339332 |
| citation_normalized_percentile.is_in_top_1_percent | False |
| citation_normalized_percentile.is_in_top_10_percent | True |